Investigational Monoclonal Agonist Antibody REGN5381 Targets NPR1 Receptor to Regulate Vascular Tone and Treat Heart Failure
An investigational monoclonal agonist antibody REGN5381 targets the membrane-bound guanylate cyclase receptor NPR1 to induce active-like receptor conformation, resulting in hemodynamic effects that preferentially lower venous pressures to treat heart failure.
